Ingenol mebutate: Potential for further development of cancer immunotherapy

Journal of Drugs in Dermatology

Volumn 11, Issue 10, 2012, Pages 1156-1157

  Doan, Hung Q ^a   Gulati, Nicholas ^b   Levis, William R ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

^b Laboratory for Investigative Dermatology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INGENOL MEBUTATE; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN KINASE C; PROTEIN P53; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; CELL DEATH; CYTOTOXICITY; DRUG MECHANISM; HUMAN; KERATINOCYTE; MITOCHONDRIAL PERMEABILITY; NONHUMAN;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; DITERPENES; HUMANS; IMMUNOLOGIC FACTORS; KERATOSIS, ACTINIC; SIGNAL TRANSDUCTION; SKIN NEOPLASMS;

EID: 84868615666     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Lebwohl M, Swanson N, Anderson LL, Melgaard A, Xu Z, Berman B. Ingenol mebutate gel for actinic keratosis. N Engl J Med. 2012;366(11):1010-1019.
2. Fallen RS, Gooderham M. Ingenol mebutate: an introduction. Skin Therapy Lett. 2012;17(2):1-3.
3. Siller G, Rosen R, Freeman M, Welburn P, Katsamas J, Ogbourne SM. PEP005 (ingenol mebutate) gel for the topical treatment of superficial basal cell carcinoma: results of a randomized phase IIa trial. Australas J Dermatol. 2010;51(2):99-105.
4. Gillespie SK, Zhang XD, Hersey P. Ingenol 3-angelate induces dual modes of cell death and differentially regulates tumor necrosis factor-related apoptosis- inducing ligand-induced apoptosis in melanoma cells. Mol Cancer Ther. 2004;3(12):1651-1658. (Pubitemid 40136721)
5. Cozzi SJ, Parsons PG, Ogbourne SM, Pedley J, Boyle GM. Induction of senescence in diterpene ester-treated melanoma cells via protein kinase Cdependent hyperactivation of the mitogen-activated protein kinase pathway. Cancer Res. 2006;66(20):10083-10091. (Pubitemid 44672062)
6. Cozzi SJ, Ogbourne SM, James C, et al. Ingenol mebutate field-directed treatment of UVB-damaged skin reduces lesion formation and removes mutant p53 patches. J Invest Dermatol. 2012;132(4):1263-1271.
7. Le TT, Gardner J, Hoang-Le D, et al. Immunostimulatory cancer chemotherapy using local ingenol-3-angelate and synergy with immunotherapies. Vaccine. 2009;27(23):3053-3062.
8. Chen Y, Fujita T, Zhang D, et al. Physical and functional antagonism between tumor suppressor protein p53 and fortilin, an anti-apoptotic protein. J Biol Chem. 2011;286(37):32575-32585.
9. Eno CO, Eckenrode EF, Olberding KE, Zhao G, White C, Li C. Distinct Roles of Mitochondria- and ER-localized Bcl-xL in Apoptosis Resistance and Ca2+ Homeostasis. Mol Biol Cell. 2012;23(13):2605-2618.
10. Susini L, Besse S, Duflaut D, et al. TCTP protects from apoptotic cell death by antagonizing bax function. Cell Death Differ. 2008;15(8):1211-1220. (Pubitemid 351984751)
11. Kim I, Xu W, Reed JC. Cell death and endoplasmic reticulum stress: disease relevance and therapeutic opportunities. Nat Rev Drug Discov. 2008;7(12):1013-1030.
12. Challacombe JM, Suhrbier A, Parsons PG, et al. Neutrophils are a key component of the antitumor efficacy of topical chemotherapy with ingenol-3-angelate. J Immunol. 2006;177(11):8123-8132. (Pubitemid 44846331)
13. Schaible UE, Winau F, Sieling PA, et al. Apoptosis facilitates antigen presentation to T lymphocytes through MHC-I and CD1 in tuberculosis. Nat Med. 2003;9(8):1039-1046. (Pubitemid 37021784)
14. Behar SM, Martin CJ, Nunes-Alves C, Divangahi M, Remold HG. Lipids, apoptosis, and cross-presentation: links in the chain of host defense against Mycobacterium tuberculosis. Microbes Infect. 2011;13(8-9):749-756.
15. Poulin LF, Salio M, Griessinger E, et al. Characterization of human DNGR-1+ BDCA3+ leukocytes as putative equivalents of mouse CD8alpha+ dendritic cells. J Exp Med. 2010;207(6):1261-1271.
16. Holzer AM, Kaplan LL, Levis WR. Haptens as drugs: contact allergens are powerful topical immunomodulators. J Drugs Dermatol. 2006;5(5):410-416.
17. Felicetti F, Errico MC, Bottero L, et al. The promyelocytic leukemia zinc fingermicroRNA- 221/-222 pathway controls melanoma progression through multiple oncogenic mechanisms. Cancer Res. 2008;68(8):2745-2754. (Pubitemid 351556272)